ISTH 2022 | Simoctocog alfa for the treatment of patients with hemophilia A

Name: Simoctocog alfa for the treatment of patients with hemophilia A
Uploaded: 2022-07-11T00:00:00Z
Duration: 44 s
Description: Susan Halimeh, MD, Gerinnungszentrum Rhein-Ruhr, Duisburg, Germany, briefly comments on the efficacy of simoctocog alfa, a novel recombinant FVIIII with an extended half-life, in previously treated patients with hemophilia A. This interview took place at the 30th Congress of the International Society on Thrombosis and Haemostasis (ISTH) 2022 held in London, UK.

Susan Halimeh • 11 Jul 2022

ISTH 2022

Hemophilia Simoctocog alfa

Susan Halimeh, MD, Gerinnungszentrum Rhein-Ruhr, Duisburg, Germany, briefly comments on the efficacy of simoctocog alfa, a novel recombinant FVIIII with an extended half-life, in previously treated patients with hemophilia A. This interview took place at the 30th Congress of the International Society on Thrombosis and Haemostasis (ISTH) 2022 held in London, UK.